Skip to main content

Table 1 Demographic characteristics

From: Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study

Characteristic

hypoAlb patients

(n = 79)

NhypoAlb patients

(n = 79)

Age, years

54.9

55.1

Dialysis vintage, months

34.7

45.3

Incident HD patients,a %

15.2%

3.8%

Male, %

53.2%

53.2%

Race, %

 Black

35.4%

35.4%

 White

62.0%

62.0%

 Other

2.6%

2.6%

Hispanic/Latino, %

11.4%

26.6%

BMI, kg/m2

31.4

31.3

Baseline PB not recorded, %

34.2%

26.6%

Baseline PB recorded, %

 Calcium acetate (CaAc)

26.6%

24.1%

 Sevelamer (Sev)

36.7%

48.1%

 Lanthanum carbonate

1.3%

1.3%

 Switch between Sev/CaAc

1.3%

0.0%

Primary cause of ESRD, %

 Diabetes

54.4%

40.5%

 Hypertension

21.5%

34.2%

 Glomerulonephritis

7.6%

8.9%

 Polycystic kidney

0.0%

1.3%

 Other/ unknown

16.4%

15.2%

Comorbid conditions, %

 Diabetes

63.3%

63.3%

 Congestive heart failure

21.5%

20.3%

  1. Summary statistics are presented as mean or percentage
  2. Abbreviations: BMI body mass index, ESRD end-stage renal disease, HD hemodialysis, hypoAlb hypoalbuminemic, NhypoAlb non-hypoalbuminemic, PB phosphate binder, SO sucroferric oxyhydroxide
  3. aPatients with dialysis vintage < 120 days prior to SO initiation